Usefulness and safety of transbronchial lung cryobiopsy for reassessment of treatment in the clinical course of diffuse parenchymal lung disease

Table 1 Baseline characteristics

Number of patients	31
Age (median, range)	71.5, 47–82
Gender(male/female)	16/15
Smoking history(never/ex)	16/15
6MWT
Min SpO2(%)	88.1 ± 4.68
Total distance(m)	513 ± 84.0
Labo Data
KL-6(U/ml)	1551 ± 1135
SP-D(ng/ml)	349 ± 222
Pulmonary function test
%FVC(%)	86.4 ± 19.7
%DLCO(%)	77.7 ± 18.1
Diagnosis at SLB
IPF	4
iNSIP	5
UCIP	10
CTD-ILD	4
HP	4
Others	4
Treatment
Corticosteroids	12
Immunosuppressants	3(tacrolimus, cyclosporine, mycophenolate mofetil)
Antifibrotic drugs	5
No medication	16
LTOT	2
Period from SLB to TBLB(median, range)	49 months, 7–266 months

6MWT 6-Minute Walk Test, KL-6 Sialylated carbohydrate antigen Krebs von den Lungen-6, SP-D pulmonary Surfactant Protein-D, FVC forced vital capacity, DLCO carbon monoxide diffusing capacity, SLB surgical lung biopsy, IPF idiopathic pulmonary fibrosis, iNSIP idiopathic nonspecific interstitial pneumonia, UCIP unclassifiable interstitial pneumonia, CTD-ILD connective tissue disease-interstitial lung disease, HP hypersensitivity pneumonia, LTOT long term oxygen therapy, TBLB transbronchial lung biopsy

ISSN: 1471-2466